PEOPLE ON THE MOVE
Scynexis
Drug company Scynexis, which develops anti-infectives, has appointed David Angulo as Chief Medical Officer.
The company’s lead drug candidates, SCY-078 is in Phase II trials for the treatment of invasive fungal infections.
"David brings a wealth of relevant experience to SCYNEXIS, both through his tenure as an infectious disease physician and through clinical and corporate roles where he was instrumental in securing FDA approval for ten different products in infectious disease and dermatology," said Marco Taglietti, Chief Executive Officer.
"His proven track record in developing antifungals and his broad expertise in drug development will strengthen our clinical development efforts and support the continued development of SCY-078, a novel oral and intravenous antifungal compound."
Angulo previously worked at Brickell Biotech, GSK company Stiefel, and Schering-Plough.
